Patents by Inventor Zebunnissa Ramtoola
Zebunnissa Ramtoola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9271942Abstract: A method of producing microcapsules of the type having a core and a coating encapsulating the core comprises the steps of providing a core-forming fluid stream and a coating-forming fluid stream, providing a two spray nozzle arrangement having a core nozzle disposed concentrically about a second nozzle, spraying the core-forming fluid stream from the core nozzle and the coat-forming fluid stream from the concentric nozzle to produce microcapsules, and solidifying the microcapsules upon formation in a suitable gas. Spray drying or spray chilling may be employed as the means of solidifying the microcapsules. Microcapsules having a core and a solid coat are also described.Type: GrantFiled: November 7, 2007Date of Patent: March 1, 2016Assignee: ROYAL COLLEGE OF SURGEONS IN IRELANDInventor: Zebunnissa Ramtoola
-
Patent number: 8828431Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.Type: GrantFiled: November 30, 2012Date of Patent: September 9, 2014Assignee: Merrion Research III LimitedInventors: Kenneth Iain Cumming, Zebunnissa Ramtoola
-
Patent number: 8323689Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.Type: GrantFiled: July 14, 2008Date of Patent: December 4, 2012Assignee: Merrion Research III LimitedInventors: Kenneth I. Cumming, Zebunnissa Ramtoola
-
Patent number: 8323690Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.Type: GrantFiled: April 27, 2010Date of Patent: December 4, 2012Assignee: Merrion Research III LimitedInventors: Kenneth I. Cumming, Zebunnissa Ramtoola
-
Patent number: 8053429Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.Type: GrantFiled: September 3, 2009Date of Patent: November 8, 2011Assignee: Merrion Research III LimitedInventors: Kenneth I. Cumming, Zebunnissa Ramtoola
-
Publication number: 20110212180Abstract: A method of producing microcapsules of the type having a core and a coating encapsulating the core comprises the steps of providing a core-forming fluid stream and a coating-forming fluid stream, providing a two spray nozzle arrangement having a core nozzle disposed concentrically about a second nozzle, spraying the core-forming fluid stream from the core nozzle and the coat-forming fluid stream from the concentric nozzle to produce microcapsules, and solidifying the microcapsules upon formation in a suitable gas. Spray drying or spray chilling may be employed as the means of solidifying the microcapsules. Microcapsules having a core and a solid coat are also described.Type: ApplicationFiled: November 7, 2007Publication date: September 1, 2011Applicant: ROYAL COLLEGE OF SURGEONS IN IRELANDInventor: Zebunnissa Ramtoola
-
Publication number: 20100209499Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.Type: ApplicationFiled: April 27, 2010Publication date: August 19, 2010Inventors: Kenneth I. Cumming, Zebunnissa Ramtoola
-
Publication number: 20100074948Abstract: A method of producing a fast-melt tablet comprises the steps of forming a mixture of components, the mixture comprising at least one fast dissolving sugar alcohol, at least one disintegrant or osmotic agent, and at least one an active component, blending the mixture for a period of time, and directly compressing the blended mixture at a compression force of typically between 5 and 2O kN to form the fast-melt tablet. The process of the invention does not involve any granulation step, thereby making the process more energy efficient and cost effective. The fast dissolving sugar alcohol is selected from the group comprising: mannitol; sorbitol; erythritol; xylitol; lactose; dextrose; and sucrose, and comprises at least 50%, preferably at least 60%, and more preferably at least 70%, of the tablet (w/w). The active component is suitably provided in the form of microparticles or microcapsules having an average diameter of less than 125 microns.Type: ApplicationFiled: April 3, 2008Publication date: March 25, 2010Applicant: Royal College of Surgeons in IrelandInventors: Zebunnissa Ramtoola, Ritesh Pabari, John Kelly
-
Patent number: 7658938Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.Type: GrantFiled: February 22, 2000Date of Patent: February 9, 2010Assignee: Merrion Reasearch III LimitedInventors: Kenneth Iain Cumming, Zebunnissa Ramtoola
-
Publication number: 20100028421Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.Type: ApplicationFiled: September 3, 2009Publication date: February 4, 2010Inventors: Kenneth I. Cumming, Zebunnissa Ramtoola
-
Publication number: 20080275001Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.Type: ApplicationFiled: July 14, 2008Publication date: November 6, 2008Inventors: Kenneth I. Cumming, Zebunnissa Ramtoola
-
Publication number: 20070196464Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to promote absorption of the bisphosphonate at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.Type: ApplicationFiled: April 7, 2006Publication date: August 23, 2007Applicant: Merrion Research I LimitedInventors: Kenneth Cumming, Zebunnissa Ramtoola, Thomas Leonard
-
Publication number: 20070148228Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising an HDAC inhibitor in combination with an enhancer to promote absorption of the HDAC inhibitor at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.Type: ApplicationFiled: June 9, 2006Publication date: June 28, 2007Applicant: Merrion Research I LimitedInventors: Kenneth Cumming, Zebunnissa Ramtoola, Thomas Leonard
-
Publication number: 20040180086Abstract: Gastro-retentive dosage forms for prolonged delivery of levodopa and carbidopalevodopa combinations are described. The dosage forms comprise a tablet containing the active ingredient and a gas-generating agent sealed within an expandable, hydrophilic, water-permeable and substantially gas-impermeable membrane. Upon contact with gastric fluid, the membrane expands as a result of the release of gas from the gas-generating agent in the tablet. The expanded membrane is retained in the stomach for a prolonged period of time up to 24 hours or more during which period the active ingredient is released from the tablet providing delivery of levodopa to the site of optimum absorption in the upper small intestine.Type: ApplicationFiled: October 10, 2003Publication date: September 16, 2004Inventors: Zebunnissa Ramtoola, Kenneth I. Cumming, Mary L. Martin
-
Publication number: 20030091623Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.Type: ApplicationFiled: February 22, 2000Publication date: May 15, 2003Inventors: Kenneth Iain Cumming, Zebunnissa Ramtoola